{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-057934","form_type":"8-K","ticker":"CLB","cik":"0001958086","company_name":"Core Laboratories Inc. /DE/","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.306909+00:00","generated_at":"2026-06-02T04:16:57.618215+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Annual meeting results: all four proposals approved by shareholders","bullets":["Class III directors Lawrence Bruno and Kwaku Temeng re-elected with 37.4M and 33.0M votes for respectively.","Ratification of KPMG as auditor for FY2024 approved: 40.4M for, 0.8M against.","Advisory vote on executive compensation passed: 36.4M for, 1.8M against.","Amendment to 2020 Long-Term Incentive Plan (increase shares, extend to 2034) approved: 36.7M for, 1.5M against."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-057934","json":"https://secwatch.observer/filing/0000950170-24-057934.json","markdown":"https://secwatch.observer/filing/0000950170-24-057934.md","text":"https://secwatch.observer/filing/0000950170-24-057934.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958086/000095017024057934/0000950170-24-057934-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958086/000095017024057934/clb-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:16:57.618215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0047641c3df8589dce767ddcd2f49c6a7c22e296","claim":"Core Laboratories Inc. /DE/ shareholders approved Election of Class III Directors: Lawrence Bruno and Kwaku Temeng at the 2024-05-08 meeting.","evidence_excerpt":"Proposal 1 – Election of Class III Directors : The election of each Class III director was approved as follows: Nominee For Withheld Broker Non-Votes Lawrence Bruno 37,354,023 962,528 2,919,136 Kwaku Temeng 33,030,809 5,285,742 2,919,136","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958086/000095017024057934/0000950170-24-057934-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"8b7091afd0661f7eec731cf7513d1dcba854fbb2","claim":"Core Laboratories Inc. /DE/ shareholders approved Amendment and restatement of the Company's 2020 Long-Term Incentive Plan to increase shares and extend term through May 8, 2034 at the 2024-05-08 meeting.","evidence_excerpt":"Proposal 4 – Approving the Amendment of the Company’s Long-Term Incentive Plan : The amendment and restatement of the Company’s 2020 Long-Term Incentive Plan, the principal purposes of which are to (i) increase the number of shares authorized thereunder and (ii) extend the term of such plan through May 8, 2034, was approved as follows: For Against Abstentions Broker Non-Votes 36,742,268 1,468,975 105,308 2,919,136","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958086/000095017024057934/0000950170-24-057934-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"a3812c5f24c3160ef6bb53c13be86257b3c2ead2","claim":"Core Laboratories Inc. /DE/ shareholders approved Advisory vote on compensation of named executive officers at the 2024-05-08 meeting.","evidence_excerpt":"Proposal 3 – Approving the Compensation of the Company’s Executive Officers : An advisory vote on the compensation of the Company’s named executive officers was approved as follows: For Against Abstentions Broker Non-Votes 36,411,684 1,822,497 82,370 2,919,136","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958086/000095017024057934/0000950170-24-057934-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"ea3a66120f3b35e8bc315472359796666617cb8d","claim":"Core Laboratories Inc. /DE/ shareholders approved Ratification of appointment of KPMG LLP as independent registered public accountant for the year ending December 31, 2024 at the 2024-05-08 meeting.","evidence_excerpt":"Proposal 2 – Appointment of KPMG as Independent Registered Public Accountant : The ratification of the appointment of KPMG as the Company’s independent registered public accountant for the fiscal year ending December 31, 2024 was approved as follows: For Against Abstentions Broker Non-Votes 40,402,356 802,763 30,568 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958086/000095017024057934/0000950170-24-057934-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}